Abstract
The Rab family of GTPases contains over 60 genes in the human genome and contributes to regulation of intracellular membrane trafficking along endocytic and exocytic pathways as well as specialized pathways in specific cell types. It has become increasingly clear that disruption of the intracellular membrane trafficking system at different stages can cause various diseases. In the past decade, altered expression levels and mutations of Rab GTPases have been associated with diseases such as cancer, Alzheimers disease, and various genetic disorders. This review discusses the specific Rab GTPases and their involvement in the diseases.
Keywords: Rab, GTPase, GTP-binding protein, cancer, genetic disorder, Alzheimer's disease, Carpenter syndrome, Griscelli syndrome, Hermansky-Pudlak Syndrome, mental retardation
Current Drug Targets
Title: Rab GTPases, Membrane Trafficking and Diseases
Volume: 12 Issue: 8
Author(s): Guangpu Li
Affiliation:
Keywords: Rab, GTPase, GTP-binding protein, cancer, genetic disorder, Alzheimer's disease, Carpenter syndrome, Griscelli syndrome, Hermansky-Pudlak Syndrome, mental retardation
Abstract: The Rab family of GTPases contains over 60 genes in the human genome and contributes to regulation of intracellular membrane trafficking along endocytic and exocytic pathways as well as specialized pathways in specific cell types. It has become increasingly clear that disruption of the intracellular membrane trafficking system at different stages can cause various diseases. In the past decade, altered expression levels and mutations of Rab GTPases have been associated with diseases such as cancer, Alzheimers disease, and various genetic disorders. This review discusses the specific Rab GTPases and their involvement in the diseases.
Export Options
About this article
Cite this article as:
Li Guangpu, Rab GTPases, Membrane Trafficking and Diseases, Current Drug Targets 2011; 12 (8) . https://dx.doi.org/10.2174/138945011795906561
DOI https://dx.doi.org/10.2174/138945011795906561 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Viral Based Gene Therapy for Prostate Cancer
Current Gene Therapy Tapasin and Human Leukocyte Antigen Class I Dysregulation Correlates with Survival in Glioblastoma Multiforme
Anti-Cancer Agents in Medicinal Chemistry Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design Recent Advances in Combined Modality Therapy for Locally Advanced Head and Neck Cancer
Current Cancer Drug Targets Matrine: Bioactivities and Structural Modifications
Current Topics in Medicinal Chemistry Retinoids as Differentiating Agents in Oncology: A Network of Interactions with Intracellular Pathways as the Basis for Rational Therapeutic Combinations
Current Pharmaceutical Design Is Small Really Beautiful? Nanosensors and Low Abundance Biomarkers for Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Across the Universe of K-Ras Mutations in Non-Small-Cell-Lung Cancer
Current Pharmaceutical Design Editorial (Thematic Issue: Anticancer Natural Compounds: Molecular Mechanisms and Functions. Part I)
Current Genomics Selection and Characterization of Human Anti-MAGE-A1 scFv and Immunotoxin
Anti-Cancer Agents in Medicinal Chemistry Platinum-Based Agents for Individualized Cancer Treatment
Current Molecular Medicine CEBP Epigenetic Dysregulation as a Drug Target for the Treatment of Hematologic and Gynecologic Malignancies
Current Drug Targets The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors
Current Pharmaceutical Design The Role of E-Cadherin Down-Regulation in Oral Cancer: CDH1 Gene Expression and Epigenetic Blockage
Current Cancer Drug Targets The Role of XRCC4 in Carcinogenesis and Anticancer Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery Potential Therapeutic Targets of Curcumin, Most Abundant Active Compound of Turmeric Spice: Role in the Management of Various Types of Cancer
Recent Patents on Anti-Cancer Drug Discovery Molecular Targets from VHL Studies into the Oxygen-Sensing Pathway
Current Cancer Drug Targets Cancer Immunotherapy: Battling Tumors with Gene Vaccines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Tissue-Specific Therapeutic Targeting of p53 in Cancer: One Size Does Not Fit All
Current Pharmaceutical Design The Dichloromethane Fraction of <i>Vernonia cinerea</i> Impart Pro-Apoptotic, Genotoxic, Cell Cycle Arrest, and Drug Efflux Inhibitory Effects on Human Adenocarcinoma Cells
Recent Patents on Anti-Cancer Drug Discovery